Neoadjuvant Chemotherapy in Stage III NSCLC
| Autor: | Mohammad Jahanzeb, Jeffrey W. Allen |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Oncology
Clinical Trials as Topic medicine.medical_specialty Chemotherapy Lung Neoplasms business.industry medicine.medical_treatment Stage III NSCLC Induction chemotherapy Neoadjuvant Therapy respiratory tract diseases Clinical trial Chemotherapy Adjuvant Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Advanced disease Humans Non small cell Stage (cooking) business Neoadjuvant therapy Neoplasm Staging |
| Zdroj: | Journal of the National Comprehensive Cancer Network. 6:285-293 |
| ISSN: | 1540-1413 1540-1405 |
| Popis: | Non-small cell lung cancer (NSCLC) continues to be the leading cause of cancer-related mortality in the United States. Current standard care for treating NSCLC is surgical resection, when feasible, followed by adjuvant chemotherapy in stages II and III. Neoadjuvant or induction chemotherapy may have several potential advantages compared with adjuvant chemotherapy and has been evaluated in randomized and nonrandomized clinical trials in NSCLC. This article reviews the data for neoadjuvant chemotherapy in NSCLC with a particular focus on regionally advanced disease (stage III) that is still amenable to surgical resection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|